- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.03. | Radiopharm Theranostics: New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution | 128 | GlobeNewswire (Europe) | Data presented at European Molecular Imaging Meeting (EMIM 2025) for imaging with 68Ga-RAD202 confirms specific accumulation in the tumor, favorable biodistribution and low uptake in non-target organs... ► Artikel lesen | |
| 17.03. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 17.03. | Radiopharm has seen breast cancer tumour reductions in first-phase trials | 2 | The Market Herald Australia | ||
| 16.03. | RADIOPHARM THERANOSTICS LIMITED: New RAD202 data confirms positive tumor uptake | 1 | ASX | ||
| RADIOPHARM THERANOSTICS Aktie jetzt für 0€ handeln | |||||
| 12.03. | B.Riley sets $15 target on Radiopharm Theranostics stock | 2 | Investing.com | ||
| 11.03. | RADIOPHARM THERANOSTICS LIMITED: Participation in Leerink, NWR healthcare conferences | - | ASX | ||
| 07.03. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 05.03. | RADIOPHARM THERANOSTICS LIMITED: Update - Notification regarding unquoted securities - RAD | - | ASX | ||
| 05.03. | RADIOPHARM THERANOSTICS LIMITED: Notification regarding unquoted securities - RAD | - | ASX | ||
| 28.02. | RADIOPHARM THERANOSTICS LIMITED: Half Year Report and Appendix 4D 31 December 2024 | 2 | ASX | ||
| 24.02. | RADIOPHARM THERANOSTICS LIMITED: RAD to present at TD Cowen Annual Healthcare Conference | 3 | ASX | ||
| 23.02. | RADIOPHARM THERANOSTICS LIMITED: Notification of cessation of securities - RAD | - | ASX | ||
| 23.02. | RADIOPHARM THERANOSTICS LIMITED: Change of Director's Interest Notice (IT) | - | ASX | ||
| 18.02. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 16.02. | RADIOPHARM THERANOSTICS LIMITED: Participation in B Riley Securities Radiopharma Conference | - | ASX | ||
| 10.02. | Radiopharm Theranostics: New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases | 174 | GlobeNewswire (Europe) | Successful detection of brain metastases using RAD 101 (18F-Pivalate) in a novel multiparametric imaging methodology (PET-mpMRI) study across 22 patients.All brain metastases, regardless of whether... ► Artikel lesen | |
| 10.02. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 09.02. | RADIOPHARM THERANOSTICS LIMITED: Clinical trial data shows RAD 101 detects Brain Metastases | 1 | ASX | ||
| 30.01. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 30.01. | ASX Quarterly Health Wrap: Bioxyne revenue up 77%, Radiopharm lists on Nasdaq | 2 | Stockhead |
Seite:
1 2 3 4 Weiter >>
66 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 40,930 | 0,00 % | Illumina, Tempus AI To Collaborate To Accelerate Genomic AI Innovation | SAN DIEGO (dpa-AFX) - Illumina Inc. (ILMN) and Tempus AI, Inc. (TEM), Tuesday announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,640 | 0,00 % | Why ADMA Biologics, Inc. (ADMA) Skyrocketed On Tuesday? | ||
| STRUCTURE THERAPEUTICS | 23,100 | 0,00 % | JMP maintains $87 target on Structure Therapeutics shares | ||
| ARCELLX | 60,93 | -1,76 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 13,300 | 0,00 % | Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) | - Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM -- Four-week treatment with EDG-7500 demonstrated... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 25,210 | 0,00 % | Summit Therapeutics retains $32 target from JMP | ||
| IMMUNOVANT | 14,460 | -4,55 % | Immunovant Inc.: Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 | Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of ImmunovantPete Salzmann, M.D. retired from his role as Immunovant CEO... ► Artikel lesen | |
| BEAM THERAPEUTICS | 18,230 | 0,00 % | Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration | U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S. CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,420 | 0,00 % | Recursion lizenziert HealthVerity-Echtweltdaten für klinische Studien | ||
| ARS PHARMACEUTICALS | 14,330 | -3,70 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates | $7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 7,140 | +4,39 % | Day One Biopharmaceuticals, Inc.: Day One Reports Third Quarter 2024 Financial Results and Corporate Progress | Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call... ► Artikel lesen | |
| DYNE THERAPEUTICS | 9,330 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments | - Vikram Ranade, PhD, appointed as chief business officer - - Ranjan Batra, PhD, appointed as chief scientific officer - - Oxana Beskrovnaya, PhD, transitioning to chief innovation officer - WALTHAM... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 37,060 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 13,520 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Chief Financial Officer Transition | WESTLAKE VILLAGE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 13,240 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's ... | - Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile... ► Artikel lesen |
RADIOPHARM THERANOSTICS LIMITED ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -4,90 % bei einem Aktienkurs von 4,080 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RADIOPHARM THERANOSTICS LIMITED ADR finden Sie auf Wallstreet Online.
